1168 results about "Endogeny" patented technology

The invention discloses a gene and a protein for adjusting tobacco polyphenol aroma substances and application of the gene and the protein. The gene is a tobacco NtMYB28 gene, and the CDS sequence of the tobacco NtMYB28 gene is as shown in SEQ ID No. 1. The invention further discloses application of the tobacco NtMYB28 gene in regulating the content of endogenous polyphenol substances in tobacco and regulating and controlling the metabolic pathway of phenylpropane in tobacco. The key gene NtMYB28 capable of simply and effectively adjusting the content of polyphenol substances in tobacco and the metabolic pathway of phenylpropane is found, and the gene can be applied to efficient cultivation of new high-aroma tobacco materials and development and utilization of new high-value functional tobacco germplasm.

The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1 and application thereof, and relates to the technical field of biology. The invention provides an enhancer RNA (Ribonucleic Acid) molecule MZGAe1. The nucleotide sequence of the enhancer RNA molecule MZGAe1 is as shown in SEQ ID NO: 1; meanwhile, the invention further provides a specific sgRNA sequence for activating the molecule in a targeted manner and a recombinant vector of the specific sgRNA sequence. Expression of endogenous MZGAe1 of cells is specifically activated by adopting a CRISPR activation technology, and conversion of mouse embryonic stem cells to bicellular-like cells can be efficiently promoted. By providing a brand-new endogenous targeted MZGAe1 accurate activation tool, the efficient transformation of wild mouse embryonic stem cells to bicellular cells can be realized only under the condition of endogenous activation of single enhancer RNA molecule MZGAe1, the proportion is at least increased by 5%, the expression of a totipotent marker gene ZSCAN4 is activated, and the expression of the totipotent marker gene ZSCAN4 is promoted. And an efficient and specific brand-new research tool and scheme are provided for researching zygote genome activation, embryonic development early events and cell reprogramming.

The invention discloses a Taq DNA polymerase mutant as well as a preparation method and application thereof, and relates to the technical field of biology. The Taq DNA polymerase mutant is mutation on the basis of a wild type Taq DNA polymerase amino acid sequence as shown in SEQ ID NO.1, and comprises at least one of amino acid mutation L345E, L352D and S438M. The Taq DNA polymerase mutant has excellent tolerance to urea, and solves the dual technical problems that complex biological samples containing endogenous inhibitors such as urea can be efficiently amplified, and the Taq DNA polymerase mutant is compatible with difficult PCR reactions which take urea as an additive to optimize a high GC template and the like. Therefore, the mutant is a molecular biology tool enzyme which is wider in applicability and more stable and reliable in performance.

The invention belongs to the field of biological medicine and material science, and particularly relates to an intelligent response type piezoelectric nanofiber dressing and a preparation method and application thereof. According to the preparation method, polyvinylidene fluoride-trifluoroethylene, a high polymer material and inorganic nanoparticles are blended and spun through an electrostatic spinning technology, and then a photo-thermal component coating is subjected to surface in-situ oxidation and self-polymerization, so that the composite fiber membrane is prepared. Under the stimulation of ultrasound (US) and near-infrared laser (Laser), the fiber membrane can cooperatively activate the piezoelectric effect and the photothermal effect, generate a dynamic electric field and local high temperature, realize multi-mode cooperative killing of bacteria (the antibacterial rate exceeds 99%), and simulate an endogenous electric field to promote cell migration and wound healing. The dressing has good mechanical properties (the Young modulus is 15-20 MPa), hydrophilicity (the contact angle is about 30 degrees), biocompatibility and stability, is suitable for treatment of chronic infected wounds such as diabetes mellitus and the like, and has the advantages of on-demand activation and intelligent response.

The invention discloses a plant lactobacillus with light aging resistance and an application thereof. The preservation number of the plant lactobacillus cj001 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No.35419. The fermentation supernatant of the plant lactobacillus cj001 shows good anti-aging activity and in-vitro antioxidant activity, and the growth ability of HaCaT cells is promoted. After the combined fermentation product of the plant lactobacillus cj001 and the lactobacillus paracasei Grx701 is subjected to ultraviolet radiation, the proliferation of HaCaT cells can be promoted, the endogenous antioxidant capacity of human skin cells can be enhanced, the photooxidation damage can be effectively relieved, and the combined fermentation product has a wide application value in the field of preparation of products with antioxidant, anti-aging, anti-ultraviolet damage, anti-photoaging and the like.

The invention discloses bi-crosslinking self-reinforced hydrogel based on endogenous glucose in-situ initiation as well as a preparation method and application of the bi-crosslinking self-reinforced hydrogel, and relates to the technical field of biomedical materials. The double-crosslinking self-enhanced hydrogel is prepared from the following components in concentration: 1 to 3 weight percent of hyaluronic acid-tyramine, 0.8 to 1.2 weight percent of sodium alginate, 1 to 100 mmol / L of calcium carbonate, 0.0001 to 10 U / mL of horse radish peroxidase, 20 to 40 U / mL of glucose oxidase and the balance of ultrapure water. The invention also discloses an application of the double-crosslinking self-reinforced hydrogel in preparation of a filling and repairing product for soft tissue defects. The hydrogel disclosed by the invention can be filled in a tissue defect part in an injection manner, glucose in body fluid is utilized to initiate crosslinking in situ to form the hydrogel with excellent mechanical properties and long-term stability, and meanwhile, the hydrogel is good in biocompatibility and relatively high in application value.

The invention belongs to the technical field of medical biological materials, and particularly relates to a sodium hyaluronate gel regeneration filler for injection and a preparation method and application thereof.The sodium hyaluronate gel serves as a carrier to disperse acellular matrix particles, the sodium hyaluronate gel forms a micron-sized porous structure in the cross-linking process through a microbubbling technology, and the sodium hyaluronate gel is prepared into the sodium hyaluronate gel regeneration filler for injection and the preparation method and application of the sodium hyaluronate gel regeneration filler. A local cross-linked network is strengthened by combining a secondary cross-linking process, high elastic modulus is realized while the content of sodium hyaluronate is reduced, so that the porous structure has excellent instant filling and shaping capability and controllable degradation behavior, the porous structure can promote permeation of hyaluronidase, the degradation period of the hyaluronidase is matched with the tissue regeneration process, and the tissue regeneration effect is improved. And the acellular matrix particles can continuously induce adhesion, migration, proliferation and differentiation of endogenous cells of tissues, synergistically promote in-situ tissue regeneration, effectively reduce repeated injection requirements and reduce long-term complication risks, and have a good application prospect in soft tissue filling and repairing.

To provide a method for determining when a natural therapeutic or beneficial product will exert its therapeutic or beneficial effect via a physiological mechanism of action.SOLUTION: The present invention relates to a new method that allows the evolution of medical technologies from the use of chemically or biologically defined artificial substances to self-assembling natural products obtained from natural raw materials by industrial processes that preserve their endogenous properties, thereby preserving their ability to interact with the networks of the living world (including humans), which natural products cannot be defined with classical qualitative and quantitative composition schemes. Thus, the present invention provides a new method for determining when a therapeutic or beneficial product exerts its therapeutic or beneficial effect via a physiological mechanism of action. This method provides the tools necessary for the skilled person to assess the mechanism of action of a therapeutic or beneficial product, which has become a relevant feature to assess with new developments in regulatory regimes for medical devices and nutraceuticals, for which there is no method available in the art.SELECTED DRAWING: None

An engineered producer cell comprising an inactivating mutation in one or more endogenous REP binding sites is provided, as are methods for producing the engineered producer cell and using the engineered producer cell to produce a recombinant viral vector and reduce producer cell genomic DNA contamination of a recombinant adeno-associated virus vector preparation.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The invention belongs to the technical field of medicines, and provides a method for screening a mutant strain and a high-virulence Seneca virus A mutant strain. The method for promoting Senecavirus A mutation provided by the invention comprises the following steps: inserting an RNAi target sequence between 3Dpol and a 3'untranslated region of an SVA starting strain; the target sequence of the RNAi contains a complementary sequence of an endogenous sequence of the miRNA. According to the research, mutagenesis is carried out on SVA by constructing a high RNAi pressure system, and a method for screening the mutant strain SVA is carried out by simulating an antiviral RNAi mechanism in a host, so that a natural evolution process of the virus is better met, a large number of stably inherited mutant strains can be obtained, and an efficient research and development means is provided for vaccine research and development aiming at the virus.

The invention relates to the technical field of biology, and discloses an efficient extraction process of SOD in silphium perfoliatum, which comprises the following steps: mixing a silphium perfoliatum superoxide dismutase crude extract, polyethylene glycol and a first salt, and adjusting the pH value to form an aqueous two-phase system to enrich SOD; adding polysaccharide hydrolase and protease into the system to carry out in-situ enzymolysis so as to degrade macromolecular impurities; after the enzymolysis is finished, adding a second salt for competitive distribution, and selectively removing the added functional enzyme to a salt phase; and finally, separating and collecting a supernatant phase rich in superoxide dismutase. By integrating aqueous two-phase extraction, in-situ enzymolysis and competitive distribution into a single reaction system, a tedious intermediate separation unit in a traditional process is replaced, and by continuous and targeted removal of endogenous macromolecular impurities and exogenous functional enzymes, the purity and specific activity of a final product are remarkably improved, so that the method is suitable for industrial production. And the biological activity of SOD is effectively protected by the mild separation conditions in the whole process.

The invention discloses a medicine composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) through a chemical small molecule combination, and the medicine composition is used for treating sepsis. According to the invention, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is activated through a time sequence, and fibroblasts from somatic cells are efficiently converted into PCLCs with high expression of genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, AHR, NQO1, QPRT and the like. When applied to treatment of sepsis, the medicine composition can improve pathological symptoms and reduce death rate by synergistically exerting anti-inflammatory, anti-oxidation, immune regulation and tissue barrier protection effects. The invention provides a novel safe treatment strategy based on non-genetically modified cells for sepsis.

The present disclosure relates to a CCL20 promoter derived from a regulatory region of the CCL20 gene, which stimulates gene expression in response to inflammation. These CCL20 promoters, which can be stimulated by endogenous or exogenous cytokines, can be used to control the timing of expression of heterologous genes. The disclosure also relates to expression cassettes or vectors comprising a CCL20 promoter of the disclosure operably linked to a nucleic acid sequence encoding, for example, a polypeptide of interest; and delivery systems (e.g., viral particles, lipid vesicles or nanoparticles) or cells comprising such expression cassettes or vectors. The disclosure also relates to the use of the promoter, expression cassette, vector, delivery system or cell in the treatment of inflammation-related diseases or for recombinant gene expression.

The invention belongs to the technical field of biochemical engineering, and discloses a production method for improving the content of odd-chain fatty acid in grease by modifying schizochytrium limacinum and optimizing a substrate and application of the method. According to the method, schizochytrium limacinum HX-308 serves as a receptor strain, high-yield odd-chain fatty acid engineering bacteria are obtained through gene overexpression and inhibition, and the high-yield odd-chain fatty acid is obtained. Accumulation of a propionyl CoA precursor pool for synthesizing odd-chain fatty acid is improved, endogenous methylmalonyl-CoA mutase coding gene MUT is inhibited, so that a competitive pathway of the odd-chain fatty acid is inhibited, and then through substrate optimization, the content of fermented grease and the content of the odd-chain fatty acid are obviously improved. The expression of related enzymes in schizochytrium limacinum is adjusted through a genetic engineering strategy to improve the odd-chain fatty acid synthesis, the synthesis and utilization of the key intermediate propionyl coenzyme A in the odd-chain fatty acid synthesis process are increased, the metabolic pathway of the propionyl coenzyme A is inhibited, and substrate optimization is assisted to improve the odd-chain fatty acid yield.

The invention provides multifunctional bionic hydrogel as well as preparation and application thereof in traumatic brain injury treatment, and belongs to the field of biomedical materials. The preparation method comprises the following steps: combining polydopamine modified hemoglobin nanoparticles with curcumin-based carbon quantum dots with anti-inflammatory activity, and embedding into bionic hyaluronic acid-collagen double-network hydrogel, so as to prepare the multifunctional bionic hydrogel. The hydrogel can effectively relieve neuron hypoxia, reduce apoptosis, promote the polarity of microglial cells to be converted into anti-inflammatory phenotype, and significantly down-regulate the expression of S100A8, thereby inhibiting pathological neural immune crosstalk. In a traumatic brain injury model, hydrogel implantation improves the pathological microenvironment, enhances endogenous nerve regeneration, and ultimately results in significant neurological function and cognitive recovery. The multifunctional bionic hydrogel prepared by the invention has a good application prospect in preparation of materials for preventing and / or treating traumatic brain injury.

The invention belongs to the technical field of photoacoustic response antibacterial dressings, and discloses PDA (at) Ag (at) Ag2S / SA / F68 / F127 antibacterial temperature-sensitive hydrogel as well as a preparation method and application thereof.The PDA (at) Ag (at) Ag2S / SA / F68 / F127 antibacterial temperature-sensitive hydrogel can complete conversion of gel and sol under the condition of 4-60 DEG C, PDA (at) Ag (at) Ag2S nano-enzyme is constructed by means of an in-situ growth method, a PDA (at) Ag (at) Ag2S nano-composite material can generate electron-hole pairs under photoacoustic combination, then reactive oxygen species (ROS) is generated, and the antibacterial temperature-sensitive hydrogel can be used for preparing antibacterial temperature-sensitive hydrogel. The photoacoustic response antibacterial effect is realized. Meanwhile, PDA (at) Ag (at) Ag2S has peroxidase (POD)-like activity, and the material can catalyze endogenous hydrogen peroxide (H2O2) in a common wound microenvironment with the pH value of 7-8 to generate reactive oxygen species (ROS) with high toxicity, such as hydroxyl free radicals (. OH), so that efficient killing of various bacteria under photoacoustic combination is realized. Synthesis conditions are mild, and the process is simple, economical and feasible. The hydrogel has thermosensitivity, can resist inflammation, stop bleeding and relieve wound pain, does not loosen after absorbing seepage, is free of residues and does not adhere to a wound surface when being removed, and a new way is provided for developing novel medical dressings for treating drug-resistant bacterial infection wounds.

The invention relates to the technical field of blood purification materials, in particular to a zirconium-titanium bimetal MOF hollow microsphere adsorbent and a preparation method and application thereof. The adsorbent is based on a Zr / Ti bimetallic node and a phosphonic acid-carboxylic acid mixed ligand, a composite MOF hollow microsphere structure with high stability and high specific surface area is constructed through a solvothermal and polymerization synergistic reaction in a water-in-oil suspension system, a phosphonic acid group and Zr are strongly coordinated to improve the stability of a framework, and the composite MOF hollow microsphere structure has a high specific surface area. The carboxylic acid group keeps the hydrophilicity of the pore channel; meanwhile, a cross-linked network of acrylamide and N, N '-methylene bisacrylamide penetrates through crystal gaps in the balling process, so that the material has excellent mechanical strength and fluid stability; and a sulphobetaine amphoteric polymer brush layer is constructed on the surface of the MOF through endogenous initiation point modification and surface in-situ controllable free radical polymerization technologies, so that protein adsorption and platelet adhesion are effectively inhibited, the blood compatibility is remarkably improved, and meanwhile, the channel accessibility is maintained to promote rapid diffusion and adsorption of bilirubin.

A microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix for liver regeneration and a preparation method. The hydrogel is prepared by means of combining fish liver decellularized extracellular matrix (dECM) and gelatin methacryloyl (GelMA), and loading induced pluripotent stem cell-derived hepatocytes (iPSC-heps) for liver regeneration. The microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix exhibits excellent biocompatibility, retains intact endogenous growth factors, maintains the biological activity of cells, ensures the effective encapsulation of the cells, and facilitates the robust functional expression of the iPSC-heps. After in-vivo transplantation, the survival rate and liver function of mice with acute liver failure are significantly improved, and liver regeneration and repair are promoted.

The invention provides in-situ forming fluid bionic hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides an injectable GelSSO / PDA (at) SDF fluid bionic niche, after in-situ photo-crosslinking, preferential and sustained release of PDA (at) SDF NPs initiates early signal amplification, which recruits EPCs and MSCs through an SDF-1 alpha / CXCR4 axis, promotes activation of the angiogenic vascular niche through an AKT signal, and repolarizes macrophages to a regenerated M2 phenotype. Subsequently, the gradual degradation of the bionic niche triggers the stable release of SSO, and the later signal is further amplified to form an osteogenic niche with transcriptional activity, thereby maintaining the MAPK / ERK-mediated MSCs osteogenic differentiation. The fluid bionic niche can form a niche conforming to defects through photopolymerization, the local immune imbalance and endogenous progenitor cell recruitment are corrected in the early stage, then formation of new vessels and lamellar bones is promoted, and finally vascularization regeneration of diabetic skull defects is achieved.

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention provides a controllable degradation magnesium-based bionic biphasic stent as well as a preparation method and application thereof. The stent comprises a porous magnesium stent, hydrogel and a ceramic coating, the porous magnesium scaffold comprises a cartilage phase scaffold and a subchondral bone phase scaffold which are arranged from top to bottom; hydrogel is arranged on pores and the outer surface of the cartilage phase scaffold, and a ceramic coating is arranged on the surface of the subchondral bone phase scaffold. From the bionic angle, the three-dimensional communicated porous magnesium stent with gradient porosity is designed by simulating the structure, mechanics and other characteristics of joint tissues (upper cartilage and lower subchondral bone); meanwhile, according to the characteristics of joint tissue components, biological properties and the like, hydrogel (an upper cartilage phase) is filled in the stent, and a bioactive ceramic coating (a lower subchondral bone phase) is prepared on the surface of the stent, so that the degradation rate of the biphasic magnesium stent is regulated and controlled, and the cytotoxicity is reduced; meanwhile, the biocompatibility and the biological activity are improved, and endogenous cartilage-subchondral bone integrated repair is realized.

This disclosure relates to cell therapy approaches for treating progranulin (PGRN) deficiencies with human induced pluripotent stem cell (hiPSC)-derived cells. Advantageously, the hiPSC-derived cells (e.g., microglia progenitor cells) described herein can cross-correct PGRN deficiencies in damaged or diseased cells while reducing the amount of endogenous cell ablation that is needed, as demonstrated by experimental results showing restoration of PGRN levels in GRN mutant cells and brain organoids.

The invention discloses a construction method and application of an animal model of Parkinson's disease, and relates to the technical field of animal models of neurodegenerative diseases. The animal model of the Parkinson's disease induces alpha-synuclein to be transmitted along an intestine-brain axis. The construction method comprises the following steps: (1) providing an SD (Sprague Dawley) rat; and (2) performing intragastric administration on the SD rat with rotenone according to the dosage of 30mg / kg / day, so as to obtain the animal model of the Parkinson's disease. The Parkinson's disease modeling method successfully simulates sequential transmission of alpha-syn along the intestine-brain axis, has the advantages of strong targeting, low death rate, endogenous pathology generation and the like, and provides a reliable platform for PD mechanism research and treatment development. According to the screening method of the medicine for treating the Parkinson's disease, the blocking effect of the medicine on PD pathology source transmission can be accurately evaluated by detecting the deposition amount of alpha-syn at multiple parts, and the defects of a traditional model are overcome; the method is suitable for research and development requirements of various drugs, and the application range is far better than that of a screening model only aiming at a single pathological link.

The invention discloses application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency, belongs to the field of gene editing treatment, and finds that the beta-nicotinamide mononucleotide (NMN) can efficiently inhibit the activity of CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13 systems in a broad-spectrum manner for the first time. The application comprises emergency blocking of off-target effect in gene editing clinical treatment, biological safety prevention and control of a virus vector gene editing system, and CRISPR activity regulation and control of in-vitro non-diagnostic purpose. Experiments show that NMN can inhibit CRISPR-mediated gene damage and cell death in a cell model, the inhibition efficiency in an in-vitro enzyme digestion system reaches 68.7%, and cell growth or transfection efficiency is not affected. The invention provides an innovative solution for safe application of CRISPR (clustered regularly interspaced short palindromic repeats) technology, and the NMN is approved to be taken orally as a health care product, so that the NMN has extremely strong clinical application potential. Compared with the existing CRISPR (clustered regularly interspaced short palindromic repeats)-resistant protein or synthetic small-molecule inhibitor, the NMN has the advantages of endogenous property, high biocompatibility, good oral safety and the like.

The invention relates to the technical field of osteoarthritis drugs, particularly discloses an application of DDX5-K45mRNA in preparation of drugs for treating and / or relieving osteoarthritis, and provides a drug delivery system for targeting chondrocytes at the same time, research finds that when DDX5-K45mRNA is added into the chondrocytes, the drug delivery system can be used for treating and / or relieving osteoarthritis. The medicine can restore DDX5-K45 lactic acid, block NF-kappa B inflammation signals, correct metabolic reprogramming (such as inhibition of abnormal glycolysis), and up-regulate cartilage protection factors such as COL2A1 and the like. The LNP is utilized to efficiently deliver DDX5-K45mRNA to cartilage cells, endogenous lactic acid modification defects are directly supplemented, the cartilage protection function of DDX5 is reconstructed, inflammatory response is inhibited, matrix degradation is reduced, the cartilage steady state is maintained fundamentally, and long-acting and safe OA treatment is achieved.

The invention relates to the technical field of medicines, and discloses an application of combination of bufalin and heme in preparation of a cancer treatment medicine. According to the invention, by means of an active metabonomics means, a key active metabolite-heme is locked through exogenous library screening and endogenous analysis, and the drug effect of bufalin is regulated by means of the active metabolite. Through verification, it is found that heme can cooperate with the synergistic drug effect in various cancer cell lines, and a new technical normal form based on an active metabolome for improving the drug effect of bufalin is provided. The pharmaceutical composition can improve the apoptosis induction ability of bufalin to different cancer cells, and provides powerful guiding significance for developing a novel treatment scheme in clinical medicine.

A peptide sequence mimicking endogenous cofilin-1 incorporates transmembrane amino acid sequences to enhance cellular uptake of the peptide drug. When cofilin peptide drugs are introduced into cancer cells, they affect cancer cell migration and invasion abilities. Furthermore, the peptide sequence can be conjugated with a chelator for cancer diagnosis.